FORM PTO-1449

U.S. Department of Commerce Atty. Docket No. Patent and Trademark Office

P28506

Application No. 10/550,013

Applicant

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					Rudolf FAHRIG et al				8 2008	
					ing Date ptember 23	3, 2005	Group 1623	JOIN 1 8 2000		
			U.S. PATE	NT DOCUM	IENTS			176	OE SHE	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAM	мE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		1								
									· · · · · · · · · · · · · · · · · · ·	
	-				. ,					
		1			,					
			-							
			*						-	
	_									
			FOREIGN PA	TENT DOC	CUMENTS	S				
:		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION YES NO		
		OTHER ROCKMEN	NTC (I I I'	A 41 TD:	41- D-4- 1	D				
	1	OTHER DOCUMEN						as and nam	anaatia	
		Fahrig et al., RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients, Anti-Cancer Drugs 2006, 17:1045-1056.								
	2	Fahrig et al., Inhibition of Induced Chemoresistance by Cotreatment with (E)-5-(2-Bromovinyl)-2'-Deoxyuridine (RP101), Cancer Research 63, 5745-5753, September 15, 2003.								
	3	U.S. Patent Application 11/853,540, filed September 11, 2007.								
							*			
EXAMINER					DATE CONSIDERED					
*CV A MINICE) . Ini	tial if aitation considered subst	han an mat aitatia			AL MOED CO	10. dun lin a 4h.		:C :-	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.